Drug resistance in multiple myeloma: Latest findings and new concepts on molecular mechanisms

Oncotarget

Volumn 4, Issue 12, 2013, Pages 2186-2207

  Abdi, Jahangir ^a   Chen, Guoan ^b   Chang, Hong ^c,d,e  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NANCHANG UNIVERSITY   (China)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Oncotargets

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOTCH RECEPTOR; POMALIDOMIDE; PROTEASOME INHIBITOR; PROTEIN P53; WNT PROTEIN;

ARTICLE; BONE MARROW; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; DNA METHYLATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TRANSPORT; EPIGENETICS; GENE EXPRESSION PROFILING; GENE MUTATION; GENOME ANALYSIS; GENOMIC INSTABILITY; HEMATOLOGIC MALIGNANCY; HOMOLOGOUS RECOMBINATION; HUMAN; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NONHUMAN; ONCOGENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; TUMOR MICROENVIRONMENT;

ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION;

EID: 84891909864     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1497     Document Type: Article

References (253)

1. Anderson KC and Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol. 2011; 6:249-274.
2. Kyle RA and Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol. 2006; 134(6):573-589.
3. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, Kyle RA, Gertz MA, Greipp PR and Dewald GW. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002; 100(4):1417-1424.
4. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, et al. The molecular classification of multiple myeloma. Blood. 2006; 108(6):2020-2028.
5. Agarwal JR and Matsui W. Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis. Anticancer Agents Med Chem. 2010; 10(2):116-120.
6. Ullah MF. Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev. 2008; 9(1):1-6.
7. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002; 53:615-627.
8. Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med. 2000; 247(5):521-534.
9. Garraway LA and Janne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2012; 2(3):214-226.
10. Tan DS, Gerlinger M, Teh BT and Swanton C. Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference. Eur J Cancer. 2010; 46(12):2166-2177.
11. Raaijmakers MH. ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia. Leukemia. 2007; 21(10):2094-2102.
12. Marie JP. Drug resistance in hematologic malignancies. Curr Opin Oncol. 2001; 13(6):463-469.
13. Liu YY, Han TY, Giuliano AE and Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 2001; 15(3):719-730.
14. Wallington-Beddoe CT, Bradstock KF and Bendall LJ. Oncogenic properties of sphingosine kinases in haematological malignancies. Br J Haematol. 2013; 161(5):623-638.
15. Ricci C, Onida F and Ghidoni R. Sphingolipid players in the leukemia arena. Biochim Biophys Acta. 2006; 1758(12):2121-2132.
16. Yang M, Li W, Fan D, Yan Y, Zhang X, Zhang Y and Xiong D. Expression of ABCB5 gene in hematological malignances and its significance. Leuk Lymphoma. 2012; 53(6):1211-1215.
17. Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralt SA and June CH. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant. 2010; 16(6):709-728.
18. Wang SLaJ. The resistance mechanisms of proteasome inhibitor bortezomib. Biomarker Research. 2013; 1(13):1-9.
19. Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, Johnson DC, Gonzalez D, Dagrada GP, Protheroe RK, Konn ZJ, Stockley DM, Gregory WM, Davies FE, Ross FM and Morgan GJ. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010; 116(15):e56-65.
20. Shammas MA, Shmookler Reis RJ, Koley H, Batchu RB, Li C and Munshi NC. Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood. 2009; 113(10):2290-2297.
21. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009; 23(12):2210-2221.
22. Boyd KD, Pawlyn C, Morgan GJ and Davies FE. Understanding the molecular biology of myeloma and its therapeutic implications. Expert Rev Hematol. 2012; 5(6):603-617.
23. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002; 99(5):1745-1757.
24. Kalff A and Spencer A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J. 2012; 2:e89.
25. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, Belch AR and Pilarski LM. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003; 101(4):1520-1529.
26. Jaksic W, Trudel S, Chang H, Trieu Y, Qi X, Mikhael J, Reece D, Chen C and Stewart AK. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol. 2005; 23(28):7069-7073.
27. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ and Greipp PR. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003; 101(11):4569-4575.
28. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ, Van Wier SA, Ahmann GJ and Fonseca R. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005; 106(8):2837-2840.
29. Chang H, Sloan S, Li D, Zhuang L, Yi QL, Chen CI, Reece D, Chun K and Keith Stewart A. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol. 2004; 125(1):64-68.
30. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359(9):906-917.
31. Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, Marit G, Benboubker L, Voillat L, Mathiot C, Kolb B, Macro M, Campion L, Wetterwald M, Stoppa AM, Hulin C, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010; 28(30):4630-4634.
32. Chang H, Trieu Y, Qi X, Xu W, Stewart KA and Reece D. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res. 2007; 31(6):779-782.
33. Chang H, Trieu Y, Qi X, Jiang NN, Xu W and Reece D. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains. Leuk Res. 2011; 35(1):95-98.
34. Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE, Mansoor A, Chen C, Masih-Khan E, Trieu Y, Bruyere H, Stewart DA and Bahlis NJ. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009; 114(3):522-525.
35. Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau JL and Bataille R. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood. 2001; 98(10):3082-3086.
36. Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A, Dewald G, Kirsch IR, Bergsagel PL and Kuehl WM. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A. 2000; 97(1):228-233.
37. Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T, Mulligan G, Chesi M, Bergsagel PL and Fonseca R. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia. 2011; 25(6):1026-1035.
38. Greil R, Fasching B, Loidl P and Huber H. Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis. Blood. 1991; 78(1):180-191.
39. Greco C, D'Agnano I, Vitelli G, Vona R, Marino M, Mottolese M, Zuppi C, Capoluongo E and Ameglio F. c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB. Int J Immunopathol Pharmacol. 2006; 19(1):67-79.
40. Lonial S, Mitsiades CS and Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res. 2011; 17(6):1264-1277.
41. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Larson DR, Kyle RA and Greipp PR. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004; 79(7):867-874.
42. Chang-Yew Leow C, Gerondakis S and Spencer A. MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer J. 2013; 3:e105.
43. Popovic R and Licht JD. MEK and MAF in myeloma therapy. Blood. 2011; 117(8):2300-2302.
44. Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA, Jackson GH, Davies FE and Morgan GJ. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012; 26(2):349-355.
45. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, Hollmig K, Zangarri M, Pineda-Roman M, van Rhee F, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B and Shaughnessy JD, Jr. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006; 108(5):1724-1732.
46. Inoue J, Otsuki T, Hirasawa A, Imoto I, Matsuo Y, Shimizu S, Taniwaki M and Inazawa J. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol. 2004; 165(1):71-81.
47. Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology. 2005; 10 Suppl 1:117-126.
48. Kocher O, Comella N, Tognazzi K and Brown LF. Identification and partial characterization of PDZK1: a novel protein containing PDZ interaction domains. Lab Invest. 1998; 78(1):117-125.
49. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F and Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997; 57(16):3537-3547.
50. Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, Barlogie B and Shaughnessy JD, Jr. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007; 109(11):4995-5001.
51. Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, Wu Y, Xiao F, Liu Y, Yang Y, Salama M, Li G, Tricot G and Zhan F. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget. 2010; 1(1):22-33.
52. Chang H, Ning Y, Qi X, Yeung J and Xu W. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. Br J Haematol. 2007; 139(1):51-54.
53. Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, Fenwick K, Kozarewa I, Gonzalez D, Lord CJ, Ashworth A, Davies FE and Morgan GJ. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood. 2012; 120(5):1077-1086.
54. Pollett JB, Trudel S, Stern D, Li ZH and Stewart AK. Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood. 2002; 100(10):3819-3821.
55. Grand EK, Chase AJ, Heath C, Rahemtulla A and Cross NC. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia. 2004; 18(5):962-966.
56. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471(7339):467-472.
57. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, Middha S, Asmann Y, Schmidt J, Braggio E, Keats JJ, Fonseca R, Bergsagel PL, Craig DW, Carpten JD and Stewart AK. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012; 120(5):1060-1066.
58. Hideshima T, Bergsagel PL, Kuehl WM and Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004; 104(3):607-618.
59. Kuehl WM and Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012; 122(10):3456-3463.
60. Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D, Goldschmidt H, Jauch A, Reme T, Jourdan M, Amiot M and Pellat-Deceunynck C. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2011; 96(4):574-582.
61. Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P, Attal M, Harousseau JL, Moreau P, Bataille R, Campion L, Avet-Loiseau H and Minvielle S. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol. 2008; 26(29):4798-4805.
62. Jiang A, Reece D and Chang H. Genomic stratification of multiple myeloma treated with novel agents. Leuk Lymphoma. 2012; 53(2):202-207.
63. Drach J, Ackermann J, Fritz E, Kromer E, Schuster R, Gisslinger H, DeSantis M, Zojer N, Fiegl M, Roka S, Schuster J, Heinz R, Ludwig H and Huber H. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998; 92(3):802-809.
64. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007; 109(8):3489-3495.
65. Chang H, Qi C, Yi QL, Reece D and Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood. 2005; 105(1):358-360.
66. Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, Wang S, Chen L, Barlogie B, Shaughnessy JD, Jr. and Zhan F. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood. 2008; 112(10):4235-4246.
67. Galm O, Herman JG and Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 2006; 20(1):1-13.
68. Rush LJ and Plass C. Alterations of DNA methylation in hematologic malignancies. Cancer Lett. 2002; 185(1):1-12.
69. Feinberg AP and Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983; 301(5895):89-92.
70. Brown R and Strathdee G. Epigenomics and epigenetic therapy of cancer. Trends Mol Med. 2002; 8(4 Suppl):S43-48.
71. Rossi D, Capello D, Gloghini A, Franceschetti S, Paulli M, Bhatia K, Saglio G, Vitolo U, Pileri SA, Esteller M, Carbone A and Gaidano G. Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica. 2004; 89(2):154-164.
72. Braggio E, Maiolino A, Gouveia ME, Magalhaes R, Souto Filho JT, Garnica M, Nucci M and Renault IZ. Methylation status of nine tumor suppressor genes in multiple myeloma. Int J Hematol. 2010; 91(1):87-96.
73. Seidl S, Ackermann J, Kaufmann H, Keck A, Nosslinger T, Zielinski CC, Drach J and Zochbauer-Muller S. DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer. 2004; 100(12):2598-2606.
74. Galm O, Wilop S, Reichelt J, Jost E, Gehbauer G, Herman JG and Osieka R. DNA methylation changes in multiple myeloma. Leukemia. 2004; 18(10):1687-1692.
75. Galm O, Yoshikawa H, Esteller M, Osieka R and Herman JG. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood. 2003; 101(7):2784-2788.
76. Bollati V, Fabris S, Pegoraro V, Ronchetti D, Mosca L, Deliliers GL, Motta V, Bertazzi PA, Baccarelli A and Neri A. Differential repetitive DNA methylation in multiple myeloma molecular subgroups. Carcinogenesis. 2009; 30(8):1330-1335.
77. Mateos MV, Garcia-Sanz R, Lopez-Perez R, Moro MJ, Ocio E, Hernandez J, Megido M, Caballero MD, Fernandez-Calvo J, Barez A, Almeida J, Orfao A, Gonzalez M and San Miguel JF. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol. 2002; 118(4):1034-1040.
78. Takada S, Morita K, Hayashi K, Matsushima T, Sawamura M, Murakami H and Nojima Y. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma. Eur J Haematol. 2005; 75(6):505-510.
79. Chim CS, Kwong YL, Fung TK and Liang R. Methylation profiling in multiple myeloma. Leuk Res. 2004; 28(4):379-385.
80. Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, Davies FE, Ross FM and Morgan GJ. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood. 2011; 117(2):553-562.
81. Kaiser MF, Johnson DC, Wu P, Walker BA, Brioli A, Mirabella F, Wardell CP, Melchor L, Davies FE and Morgan GJ. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood. 2013; 122(2):219-226.
82. Heuck CJ, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharyya S, Meagher R, Hu C, et al. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J Immunol. 2013; 190(6):2966-2975.
83. Christoph Heuck JM, Joseph Tariman, Natalie Pulliam, Yiting Yu,Tushar D. Bhagat, Sangeeta Nischal, Richard Meagher, Caroline Y. Hu, Amit Verma and Seema B. Singhal. Epigenomic Profiling of Multiple Myeloma Shows Widespread Stage Specific Alterations In DNA Methylation That Occur Early During Myelomagenesis. ASH congress. 2010; Abstract No. 784
84. Nojima M, Maruyama R, Yasui H, Suzuki H, Maruyama Y, Tarasawa I, Sasaki Y, Asaoku H, Sakai H, Hayashi T, Mori M, Imai K, Tokino T, Ishida T, Toyota M and Shinomura Y. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin Cancer Res. 2009; 15(13):4356-4364.
85. Smith EM, Boyd K and Davies FE. The potential role of epigenetic therapy in multiple myeloma. Br J Haematol. 2010; 148(5):702-713.
86. Richardson PG, Mitsiades CS, Laubach JP, Hajek R, Spicka I, Dimopoulos MA, Moreau P, Siegel DS, Jagannath S and Anderson KC. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res. 2013; 37(7):829-837.
87. Hajek R, Siegel D, Orlowski RZ, Ludwig H, Palumbo A and Dimopoulos MA. The Role of Hdac Inhibitors in Patients with Relapsed/Refractory Multiple Myeloma. Leuk Lymphoma. 2013.
88. Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, Atadja P, Pandiella A and San Miguel JF. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res. 2006; 66(11):5781-5789.
89. Ken Maes EM, Els Van Valckenborgh, Ivan Van Riet, Karin Vanderkerken, and Elke De Bruyne. Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma. Cancers. 2013; 5:430-461.
90. CS Chim TK Fung, R Liang. Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS. Leukemia. 2003; 17:2533-2535.
91. Epstein J, Xiao HQ and Oba BK. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood. 1989; 74(3):913-917.
92. Sonneveld P, Schoester M and de Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. J Clin Oncol. 1994; 12(8):1584-1591.
93. Cornelissen JJ, Sonneveld P, Schoester M, Raaijmakers HG, Nieuwenhuis HK, Dekker AW and Lokhorst HM. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. J Clin Oncol. 1994; 12(1):115-119.
94. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, Scheper RJ and Dalton WS. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood. 1993; 81(2):490-495.
95. Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR and Bonnet JD. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer. 1995; 75(3):815-820.
96. Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, Sonneveld P and Greipp PR. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer. 2006; 106(4):830-838.
97. Yang HH, Ma MH, Vescio RA and Berenson JR. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol. 2003; 21(22):4239-4247.
98. Buda G, Maggini V, Galimberti S, Martino A, Giuliani N, Morabito F, Genestreti G, Iacopino P, Rizzoli V, Barale R, Rossi AM and Petrini M. MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol. 2007; 137(5):454-456.
99. Drain S, Flannely L, Drake MB, Kettle P, Orr N, Bjourson AJ, Catherwood MA and Alexander HD. Multidrug resistance gene expression and ABCB1 SNPs in plasma cell myeloma. Leuk Res. 2011; 35(11):1457-1463.
100. Buda G, Ricci D, Huang CC, Favis R, Cohen N, Zhuang SH, Harousseau JL, Sonneveld P, Blade J and Orlowski RZ. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 2010; 89(11):1133-1140.
101. O'Connor R, Ooi MG, Meiller J, Jakubikova J, Klippel S, Delmore J, Richardson P, Anderson K, Clynes M, Mitsiades CS and O'Gorman P. The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol. 2013; 71(5):1357-1368.
102. Hawley TS, Riz I, Yang W, Wakabayashi Y, Depalma L, Chang YT, Peng W, Zhu J and Hawley RG. Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol. 2013; 88(4):265-272.
103. Raaijmakers MH, de Grouw EP, Heuver LH, van der Reijden BA, Jansen JH, Scheffer G, Scheper RJ, de Witte TJ and Raymakers RA. Impaired breast cancer resistance protein mediated drug transport in plasma cells in multiple myeloma. Leuk Res. 2005; 29(12):1455-1458.
104. Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS and Sullivan DM. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 2006; 108(12):3881-3889.
105. Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, Xu H, Shetty S, Chen T, Zeng Z, Shi L, Zangari M, Miles R, Bearss D, Tricot G and Zhan F. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 2013; 23(1):48-62.
106. Saha MN, Qiu L and Chang H. Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol. 2013; 6:23.
107. Vogelstein B and Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004; 10(8):789-799.
108. Farnebo M, Bykov VJ and Wiman KG. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun. 2010; 396(1):85-89.
109. Vousden KH and Prives C. Blinded by the Light: The Growing Complexity of p53. Cell. 2009; 137(3):413-431.
110. Avet-Loiseau H, Li JY, Godon C, Morineau N, Daviet A, Harousseau JL, Facon T and Bataille R. P53 deletion is not a frequent event in multiple myeloma. Br J Haematol. 1999; 106(3):717-719.
111. Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E, Henderson K, Oken M, Van Ness B, Greipp P, Rajkumar SV and Fonseca R. Clinical significance of TP53 mutation in myeloma. Leukemia. 2007; 21(3):582-584.
112. Piette J, Neel H and Marechal V. Mdm2: keeping p53 under control. Oncogene. 1997; 15(9):1001-1010.
113. Rayburn E, Zhang R, He J and Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets. 2005; 5(1):27-41.
114. Elnenaei MO, Gruszka-Westwood AM, A'Hernt R, Matutes E, Sirohi B, Powles R and Catovsky D. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A. Haematologica. 2003; 88(5):529-537.
115. Cocker HA, Hobbs SM, Tiffin N, Pritchard-Jones K, Pinkerton CR and Kelland LR. High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance. Br J Cancer. 2001; 85(11):1746-1752.
116. Wilda M, Bruch J, Harder L, Rawer D, Reiter A, Borkhardt A and Woessmann W. Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt's lymphoma in children. Leukemia. 2004; 18(3):584-588.
117. Saha MN, Jiang H, Yang Y, Zhu X, Wang X, Schimmer AD, Qiu L and Chang H. Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma. PLoS One. 2012; 7(1):e30215.
118. Saha MN, Jiang H, Mukai A and Chang H. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses. Mol Cancer Ther. 2010; 9(11):3041-3051.
119. Saha MN, Jiang H and Chang H. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways. Cancer Biol Ther. 2010; 10(6):567-578.
120. Saha MN, Jiang H, Jayakar J, Reece D, Branch DR and Chang H. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol Ther. 2010; 9(11):936-944.
121. Stuhmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C, Theurich S, Cigliano L, Manz RA, Daniel PT, Bommert K, Vassilev LT and Bargou RC. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood. 2005; 106(10):3609-3617.
122. Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP, Weinstock J, Kingsbury WD, Hideshima T, Shah PK, Minvielle S, Altun M, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012; 22(3):345-358.
123. Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH and Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: Relevance of p53 and its clinical implications. Exp Hematol. 2013; 41(8):719-730.
124. Ohki R, Nemoto J, Murasawa H, Oda E, Inazawa J, Tanaka N and Taniguchi T. Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J Biol Chem. 2000; 275(30):22627-22630.
125. Takahashi T, Suzuki M, Shigematsu H, Shivapurkar N, Echebiri C, Nomura M, Stastny V, Augustus M, Wu CW, Wistuba, II, Meltzer SJ and Gazdar AF. Aberrant methylation of Reprimo in human malignancies. Int J Cancer. 2005; 115(4):503-510.
126. Almazi JG, Mactier S, Best OG, Crossett B, Mulligan SP and Christopherson RI. Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53. Proteomics Clin Appl. 2012; 6(5-6):279-290.
127. Nair P, Muthukkumar S, Sells SF, Han SS, Sukhatme VP and Rangnekar VM. Early growth response-1-dependent apoptosis is mediated by p53. J Biol Chem. 1997; 272(32):20131-20138.
128. Yu J, Baron V, Mercola D, Mustelin T and Adamson ED. A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells. Cell Death Differ. 2007; 14(3):436-446.
129. Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J, Yaccoby S, Xiong W, Barlogie B, Shaughnessy JD, Jr. and Zhan F. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood. 2010; 115(1):61-70.
130. Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL and Kuehl WM. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood. 2010; 115(17):3541-3552.
131. Demchenko YN and Kuehl WM. A critical role for the NFkB pathway in multiple myeloma. Oncotarget. 2010; 1(1):59-68.
132. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P and Kroemer G. Targeting NF-kappaB in hematologic malignancies. Cell Death Differ. 2006; 13(5):748-758.
133. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007; 12(2):131-144.
134. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007; 12(2):115-130.
135. Klein B. Positioning NK-kappaB in multiple myeloma. Blood. 2010; 115(17):3422-3424.
136. Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T and Anderson KC. Dual inhibition of canonical and noncanonical NF-kappaB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res. 2012; 18(17):4669-4681.
137. Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K and Miyamoto S. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res. 2008; 6(8):1356-1364.
138. Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst L and Koomen JM. Monitoring a nuclear factor-kappaB signature of drug resistance in multiple myeloma. Mol Cell Proteomics. 2011; 10(11):M110 005520.
139. Mjahed H, Girodon F, Fontenay M and Garrido C. Heat shock proteins in hematopoietic malignancies. Exp Cell Res. 2012; 318(15):1946-1958.
140. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T and Anderson KC. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002; 99(22):14374-14379.
141. Davenport EL, Zeisig A, Aronson LI, Moore HE, Hockley S, Gonzalez D, Smith EM, Powers MV, Sharp SY, Workman P, Morgan GJ and Davies FE. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia. 2010; 24(10):1804-1807.
142. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2006; 107(3):1092-1100.
143. Chatterjee M, Jain S, Stuhmer T, Andrulis M, Ungethum U, Kuban RJ, Lorentz H, Bommert K, Topp M, Kramer D, Muller-Hermelink HK, Einsele H, Greiner A and Bargou RC. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood. 2007; 109(2):720-728.
144. Nimmanapalli R, Gerbino E, Dalton WS, Gandhi V and Alsina M. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. Br J Haematol. 2008; 142(4):551-561.
145. Duus J, Bahar HI, Venkataraman G, Ozpuyan F, Izban KF, Al-Masri H, Maududi T, Toor A and Alkan S. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leuk Lymphoma. 2006; 47(7):1369-1378.
146. Khong T and Spencer A. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol Cancer Ther. 2011; 10(10):1909-1917.
147. Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Catley L, Tai YT, Hayashi T, Shringarpure R, Burger R, Munshi N, Ohtake Y, Saxena S and Anderson KC. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood. 2003; 102(9):3379-3386.
148. Abe TMaM. The Importance of Notch Signaling in Myeloma Cell-Osteoclast Interactions. BoneKEy-Osteovision. 2005; 2(2):7-10.
149. Nefedova Y, Cheng P, Alsina M, Dalton WS and Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2004; 103(9):3503-3510.
150. Milner LA. Notch signaling: a key to the pathogenesis of multiple myeloma? Blood. 2004; 103:3253-3254.
151. Xu D, Hu J, De Bruyne E, Menu E, Schots R, Vanderkerken K and Van Valckenborgh E. Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma. Biochem Biophys Res Commun. 2012; 428(4):518-524.
152. Houde C, Li Y, Song L, Barton K, Zhang Q, Godwin J, Nand S, Toor A, Alkan S, Smadja NV, Avet-Loiseau H, Lima CS, Miele L and Coignet LJ. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood. 2004; 104(12):3697-3704.
153. Colombo M, Mirandola L, Platonova N, Apicella L, Basile A, Figueroa AJ, Cobos E, Chiriva-Internati M and Chiaramonte R. Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes. Leukemia. 2013; 27(5):1009-1018.
154. Xu D, Hu J, Xu S, De Bruyne E, Menu E, Van Camp B, Vanderkerken K and Van Valckenborgh E. Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation. Leukemia. 2012; 26(6):1402-1405.
155. Ostman A. The tumor microenvironment controls drug sensitivity. Nat Med. 2012; 18(9):1332-1334.
156. Kocemba KA, Groen RW, van Andel H, Kersten MJ, Mahtouk K, Spaargaren M and Pals ST. Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma. PLoS One. 2012; 7(2):e30359.
157. Chim CS, Pang R, Fung TK, Choi CL and Liang R. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia. 2007; 21(12):2527-2536.
158. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH, Lokhorst HM, Bloem AC, Clevers H, Nusse R, van der Neut R, Spaargaren M and Pals ST. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A. 2004; 101(16):6122-6127.
159. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ and Orlowski RZ. Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem. 2011; 286(13):11009-11020.
160. Kobune M, Chiba H, Kato J, Kato K, Nakamura K, Kawano Y, Takada K, Takimoto R, Takayama T, Hamada H and Niitsu Y. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. Mol Cancer Ther. 2007; 6(6):1774-1784.
161. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y and Handa H. Identification of a primary target of thalidomide teratogenicity. Science. 2010; 327(5971):1345-1350.
162. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012; 26(11):2326-2335.
163. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ and Stewart AK. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011; 118(18):4771-4779.
164. Heintel D, Rocci A, Ludwig H, Bolomsky A, Caltagirone S, Schreder M, Pfeifer S, Gisslinger H, Zojer N, Jager U and Palumbo A. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol. 2013; 161(5):695-700.
165. Broyl A, Kuiper R, van Duin M, van der Holt B, el Jarari L, Bertsch U, Zweegman S, Buijs A, Hose D, Lokhorst HM, Goldschmidt H and Sonneveld P. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood. 2013; 121(4):624-627.
166. Egan JB, Kortuem KM, Kurdoglu A, Izatt T, Aldrich J, Reiman R, Phillips L, Baker A, Shi CX, Schmidt J, Liang WS, Craig DW, Carpten JD and Stewart AK. Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. Br J Haematol. 2013; 161(5):748-751.
167. Shiratsuchi M, Muta K, Abe Y, Motomura S, Taguchi F, Takatsuki H, Uike N, Umemura T, Nawata H and Nishimura J. Clinical significance of telomerase activity in multiple myeloma. Cancer. 2002; 94(8):2232-2238.
168. Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, Tassone P, Blotta S, Protopopov A, Mitsiades C, Batchu RB, Anderson KC, Chin A, Gryaznov S and Munshi NC. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia. 2008; 22(7):1410-1418.
169. Wang ES, Wu K, Chin AC, Chen-Kiang S, Pongracz K, Gryaznov S and Moore MA. Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood. 2004; 103(1):258-266.
170. Weiss C, Uziel O, Wolach O, Nordenberg J, Beery E, Bulvick S, Kanfer G, Cohen O, Ram R, Bakhanashvili M, Magen-Nativ H, Shilo N and Lahav M. Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo. Br J Cancer. 2012; 107(11):1844-1852.
171. Diaz de la Guardia R, Catalina P, Panero J, Elosua C, Pulgarin A, Lopez MB, Ayllon V, Ligero G, Slavutsky I and Leone PE. Expression profile of telomere-associated genes in multiple myeloma. J Cell Mol Med. 2012; 16(12):3009-3021.
172. Flavia Pichiorri LDLaRIA. MicroRNAs: new players in multiple myeloma. Frontiers in Genetics. 2011; 2(Article 22).
173. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. P Natl Acad Sci USA. 2008; 105(35):12885-12890.
174. Konstantinos Dimopoulos PG, Kirsten Grønbæk. Aberrant microRNA expression in multiple myeloma. European Journal of Haematology. 2013; 91:95-105.
175. Kwan Yeung Wong XHaCSC. DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis. 2012; 33(9):1629-1638.
176. Rio-Machin A, Ferreira BI, Henry T, Gomez-Lopez G, Agirre X, Alvarez S, Rodriguez-Perales S, Prosper F, Calasanz MJ, Martinez J, Fonseca R and Cigudosa JC. Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. Leukemia. 2013; 27(4):925-931.
177. Munker R, Liu CG, Taccioli C, Alder H and Heerema N. MicroRNA Profiles of Drug-Resistant Myeloma Cell Lines. Acta Haematol-Basel. 2010; 123(4):201-204.
178. Loffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermuller J, Kretzschmar AK, Burger R, Gramatzki M, Blumert C, Bauer K, Cvijic H, Ullmann AK, Stadler PF and Horn F. Interleukin-6-dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood. 2007; 110(4):1330-1333.
179. Michael A. Tessel ALB, Nancy L. Krett, Steven T. Rosen, Preethi H. Gunaratne. Role for MicroRNAs in Regulating Glucocorticoid Response and Resistance in Multiple Myeloma. HORM CANC. 2011; 2:182-189.
180. Hao M, Zhang L, An G, Meng H, Han Y, Xie Z, Xu Y, Li C, Yu Z, Chang H and Qiu L. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma. 2011; 52(9):1787-1794.
181. Hao M, Zhang L, An G, Sui WW, Yu Z, Zou DH, Xu Y, Chang H and Qiu LG. Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. Journal of Hematology&Oncology. 2011; 4.
182. Misiewicz-Krzeminska I, Sarasquete ME, Quwaider D, Krzeminski P, Ticona FV, Paino T, Delgado M, Aires A, Ocio EM, Garcia-Sanz R, Miguel JFS and Gutierrez NC. Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication. Haematologica. 2013; 98(4):640-648.
183. Kumar M, Lu Z, Takwi AAL, Chen W, Callander NS, Ramos KS, Young KH and Li Y. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene. 2011; 30(7):843-853.
184. Schoenhals M, Kassambara A, Veyrune JL, Moreaux J, Goldschmidt H, Hose D and Klein B. Kruppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma. Haematologica. 2013; 98(9):1442-1449.
185. Li QF, Wu CT, Guo Q, Wang H and Wang LS. Sphingosine 1-phosphate induces Mcl-1 upregulation and protects multiple myeloma cells against apoptosis. Biochem Biophys Res Commun. 2008; 371(1):159-162.
186. Li QF, Wu CT, Duan HF, Sun HY, Wang H, Lu ZZ, Zhang QW, Liu HJ and Wang LS. Activation of sphingosine kinase mediates suppressive effect of interleukin-6 on human multiple myeloma cell apoptosis. Br J Haematol. 2007; 138(5):632-639.
187. O'Donnell E and Raje NS. Targeting BRAF in Multiple Myeloma. Cancer Discov. 2013; 3(8):840-842.
188. Hoang B, Zhu L, Shi Y, Frost P, Yan H, Sharma S, Goodglick L, Dubinett S and Lichtenstein A. Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. Blood. 2006; 107(11):4484-4490.
189. Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K and Raab MS. Targeting the BRAF V600E Mutation in Multiple Myeloma. Cancer Discov. 2013; 3(8):862-869.
190. Hideshima T, Mitsiades C, Tonon G, Richardson PG and Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007; 7(8):585-598.
191. Manier S, Sacco A, Leleu X, Ghobrial IM and Roccaro AM. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol. 2012; 2012:157496.
192. Meads MB, Gatenby RA and Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009; 9(9):665-674.
193. Holt RU, Baykov V, Ro TB, Brabrand S, Waage A, Sundan A and Borset M. Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. Haematologica. 2005; 90(4):479-488.
194. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012; 120(16):3260-3270.
195. Shain KH and Dalton WS. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther. 2001; 1(1):69-78.
196. Shain KH, Landowski TH and Dalton WS. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr Opin Oncol. 2000; 12(6):557-563.
197. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA and Anderson KC. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood. 1996; 87(3):1104-1112.
198. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001; 15(12):1950-1961.
199. Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA and Dalton WS. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 2009; 69(3):1009-1015.
200. Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, Kufe DW and Anderson KC. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 1997; 89(1):227-234.
201. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H and Epstein J. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood. 1994; 84(9):3063-3070.
202. Lichtenstein A, Tu Y, Fady C, Vescio R and Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol. 1995; 162(2):248-255.
203. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS and Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999; 10(1):105-115.
204. Frassanito MA, Cusmai A, Iodice G and Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood. 2001; 97(2):483-489.
205. Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA and Orlowski RZ. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res. 2007; 13(21):6469-6478.
206. Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, Nobuyoshi M, Oh I, Sato K, Suzuki T, Ozaki K, Mori M, Nagai T, Muroi K, Kano Y, Furukawa Y, et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene. 2009; 28(2):231-242.
207. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA and Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999; 93(5):1658-1667.
208. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ and Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene. 2000; 19(38):4319-4327.
209. Yanamandra N, Colaco NM, Parquet NA, Buzzeo RW, Boulware D, Wright G, Perez LE, Dalton WS and Beaupre DM. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res. 2006; 12(2):591-599.
210. Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B and Meinhardt G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood. 2004; 104(6):1825-1832.
211. Neri P, Ren L, Azab AK, Brentnall M, Gratton K, Klimowicz AC, Lin C, Duggan P, Tassone P, Mansoor A, Stewart DA, Boise LH, Ghobrial IM and Bahlis NJ. Integrin beta7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood. 2011; 117(23):6202-6213.
212. Schmidmaier R, Morsdorf K, Baumann P, Emmerich B and Meinhardt G. Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. Int J Biol Markers. 2006; 21(4):218-222.
213. Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M and Dalton WS. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 2003; 63(22):7900-7906.
214. Shain KH, Landowski TH and Dalton WS. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol. 2002; 168(5):2544-2553.
215. Nefedova Y, Landowski TH and Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia. 2003; 17(6):1175-1182.
216. Markovina S, Callander NS, O'Connor SL, Xu G, Shi Y, Leith CP, Kim K, Trivedi P, Kim J, Hematti P and Miyamoto S. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Mol Cancer. 2010; 9:176.
217. Wang X, Zhang Z and Yao C. Survivin is upregulated in myeloma cell lines cocultured with mesenchymal stem cells. Leuk Res. 2010; 34(10):1325-1329.
218. Romagnoli M, Trichet V, David C, Clement M, Moreau P, Bataille R and Barille-Nion S. Significant impact of survivin on myeloma cell growth. Leukemia. 2007; 21(5):1070-1078.
219. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM and Orlowski RZ. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2013.
220. Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, Hyodo H, Shinya E, Takahashi H, Dong H, Tamada K, Chen L, Dan K and Ogata K. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia. 2013; 27(2):464-472.
221. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, Saudemont A and Quesnel B. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007; 110(1):296-304.
222. Brito JL, Walker B, Jenner M, Dickens NJ, Brown NJ, Ross FM, Avramidou A, Irving JA, Gonzalez D, Davies FE and Morgan GJ. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica. 2009; 94(1):78-86.
223. Leich E, Weissbach S, Klein HU, Grieb T, Pischimarov J, Stuhmer T, Chatterjee M, Steinbrunn T, Langer C, Eilers M, Knop S, Einsele H, Bargou R and Rosenwald A. Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules. Blood Cancer J. 2013; 3:e102.
224. Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM and Staudt LM. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 2004; 5(2):191-199.
225. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D and Matsumoto T. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004; 104(8):2484-2491.
226. Elke De Bruyne EM, Els Van Valckenborgh, Hendrik De Raeve, Ben Van Camp, Ivan Van Riet and Karin Vanderkerken. Myeloma Cells and Their Interactions With the Bone Marrow Endothelial Cells. Current Immunology Reviews. 2007; (3):41-55.
227. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J and Yi Q. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009; 114(17):3625-3628.
228. Zheng Y, Yang J, Qian J, Qiu P, Hanabuchi S, Lu Y,WangZ, Liu Z, Li H, He J, Lin P, Weber D, Davis RE, Kwak L, Cai Z and Yi Q. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia. 2013; 27(3):702-710.
229. Martin SK, Diamond P, Gronthos S, Peet DJ and Zannettino AC. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia. 2011; 25(10):1533-1542.
230. Abdi J, Mutis T, Garssen J and Redegeld F. Characterization of the Toll-like receptor expression profile in human multiple myeloma cells. PLoS One. 2013; 8(4):e60671.
231. Jego G, Bataille R, Geffroy-Luseau A, Descamps G and Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia. 2006; 20(6):1130-1137.
232. Bohnhorst J, Rasmussen T, Moen SH, Flottum M, Knudsen L, Borset M, Espevik T and Sundan A. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia. 2006; 20(6):1138-1144.
233. Abdi J, Mutis T, Garssen J and Redegeld F. Stimulation of Toll-like receptor-1/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells. Blood Cancer J. 2013; 3:e119.
234. Brennan SK and Matsui W. Cancer stem cells: controversies in multiple myeloma. J Mol Med (Berl). 2009; 87(11):1079-1085.
235. Ghosh N and Matsui W. Cancer stem cells in multiple myeloma. Cancer Lett. 2009; 277(1):1-7.
236. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI and Jones RJ. Characterization of clonogenic multiple myeloma cells. Blood. 2004; 103(6):2332-2336.
237. Kirshner J, Thulien KJ, Martin LD, Debes Marun C, Reiman T, Belch AR and Pilarski LM. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood. 2008; 112(7):2935-2945.
238. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, Watkins DN, Huff CA and Jones RJ. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008; 68(1):190-197.
239. Reghunathan R, Bi C, Liu SC, Loong KT, Chung TH, Huang G and Chng WJ. Clonogenic Multiple Myeloma Cells have Shared stemness Signature Assocuated with Patient Survival. Oncotarget. 2013; 4(8):1230-1240.
240. Pilarski LM, Seeberger K, Coupland RW, Eshpeter A, Keats JJ, Taylor BJ and Belch AR. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol. 2002; 30(3):221-228.
241. Pilarski LM and Belch AR. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors. Clin Cancer Res. 2002; 8(10):3198-3204.
242. Bergsagel PL, Smith AM, Szczepek A, Mant MJ, Belch AR and Pilarski LM. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood. 1995; 85(2):436-447.
243. Hosen N, Matsuoka Y, Kishida S, Nakata J, Mizutani Y, Hasegawa K, Mugitani A, Ichihara H, Aoyama Y, Nishida S, Tsuboi A, Fujiki F, Tatsumi N, Nakajima H, Hino M, Kimura T, et al. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia. 2012; 26(9):2135-2141.
244. Fenghuang Zhan WZ, Maurizio Zangari, Hongwei Xu, MD, MS and Guido J. Tricot. ALDH1 Activity Identifies Chemotherapy-Resistant Multiple Myeloma Stem Cells. ASH congress. 2011; Abstract 990.
245. Yang Y, Shi J, Tolomelli G, Xu H, Xia J, Wang H, Zhou W, Zhou Y, Das S, Gu Z, Levasseur D, Zhan F and Tricot G. RARalpha2 expression confers myeloma stem cell features. Blood. 2013; 122(8):1437-1447.
246. Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz IM, Jones E, Kim J, Devereux WL, Rhodes JT, Huff CA, Beachy PA, Watkins DN and Matsui W. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A. 2007; 104(10):4048-4053.
247. Bhardwaj G, Murdoch B, Wu D, Baker DP, Williams KP, Chadwick K, Ling LE, Karanu FN and Bhatia M. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol. 2001; 2(2):172-180.
248. Merchant AA and Matsui W. Targeting Hedgehog--a cancer stem cell pathway. Clin Cancer Res. 2010; 16(12):3130-3140.
249. Brennan SK, Wang Q, Tressler R, Harley C, Go N, Bassett E, Huff CA, Jones RJ and Matsui W. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One. 2010; 5(9).
250. Gentile M, Recchia AG, Mazzone C, Lucia E, Vigna E and Morabito F. Perspectives in the treatment of multiple myeloma. Expert Opin Biol Ther. 2013; 13 Suppl 1:S1-22.
251. Misso G, Zappavigna S, Castellano M, De Rosa G, Di Martino MT, Tagliaferri P, Tassone P and Caraglia M. Emerging pathways as individualized therapeutic target of multiple myeloma. Expert Opin Biol Ther. 2013; 13 Suppl 1:S95-109.
252. Usmani SZ and Chiosis G. HSP90 inhibitors as therapy for multiple myeloma. Clin Lymphoma Myeloma Leuk. 2011; 11 Suppl 1:S77-81.
253. Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC and Tiedemann RE. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013; 24(3):289-304.